Seagen Inc.
Combination of CD33 antibody drug conjugates with chemotherapeutic agents

Last updated:

Abstract:

This invention relates to treatment of cancer using a CD33 antibody drug conjugate in combination with chemotherapeutic agents.

Status:
Grant
Type:

Utility

Filling date:

2 Jun 2017

Issue date:

7 Sep 2021